Skip to main content
Skip to content
Case File
d-35209House OversightOther

Market Overview of Publicly Traded Cannabis Companies Across U.S., Canadian, and Australian Exchanges

The passage provides aggregate financial data on cannabis‑related publicly traded firms and outlines exchange listing requirements. It contains no specific allegations, names, transactions, or links t Most cannabis companies trade on OTC in the U.S. due to lax regulations. Canadian exchanges (TSX, TSXV, CSE) have varying listing standards. CSE permits U.S. cannabis operations, unlike TSX/TSXV.

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024755
Pages
1
Persons
0
Integrity
No Hash Available

Summary

The passage provides aggregate financial data on cannabis‑related publicly traded firms and outlines exchange listing requirements. It contains no specific allegations, names, transactions, or links t Most cannabis companies trade on OTC in the U.S. due to lax regulations. Canadian exchanges (TSX, TSXV, CSE) have varying listing standards. CSE permits U.S. cannabis operations, unlike TSX/TSXV.

Tags

regulatory-environmentfinancial-datacannabis-industryhouse-oversightstock-markets

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
KR L PI L AC EL CA TA CHAPTER VII Capital Markets for Cannabis Companies the NYSE are two of the largest and most recognized stock exchanges in the world, with stringent listing, trading and corporate governance requirements. Conversely, the OTC has much less stringent requirements; as a result, most publicly traded cannabis-related companies are traded on the OTC. In Canada, cannabis-related companies are traded on the Toronto Stock Exchange (TSX), the TSX Venture Exchange (TSXV), which is an affiliate of the TSX, and the Canadian Securities Exchange (CSE). The TSX is one of the world’s largest stock exchanges and, similar to Nasdaq and the NYSE, has stringent listing, trading and corporate governance requirements. The TSXV focuses on companies with small market capitalization and has less stringent listing requirements than the TSX. The CSE is focused on micro capitalization and emerging growth companies, and it has the least stringent listing requirements of the primary Canadian exchanges. In order to be listed on either the TSX or the TSXV, a company is required to be in compliance with Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and all applicable laws in jurisdictions within which it operates. (Operations of listed companies are restricted in jurisdictions, such as the United States, where cannabis is federally prohibited.) Unlike the TSX and TSXV, the CSE has allowed companies listed on its exchange to invest in, acquire and otherwise operate cannabis-related businesses in the United States. The following table provides a summary of the cannabis-related companies traded on U.S., Cana- dian and Australian stock markets. As stated previously, many cannabis-related companies are traded on more than one market to attract additional investors and facilitate trading in multiple jurisdictions. For example, most companies traded on the Canadian markets are also traded on the OTC. Summary of Publicly Traded Cannabis-Related Companies (As of November 30, 2017) Average ($U.S. millions) Number of Market Enterprise LTM LTM Companies Value Value Cash Debt Revenue EBITDA Nasdaq 4 —$1,033.6 $884.5 $153.6 $4.5 $44.0 -$81.1 NYSE 1 63.5 41.3 22.2 0.0 46 -1.2 NYSE American Z 152.1 145.7 78 1.4 Us -6.5 OTC 212 46.3 65.5 5.7 25.0 14.0 0.2 United States 219 $65.5 $81.2 $8.5 $24.3 $14.5 -$1.4 Toronto Stock Exchange (TSX) 6 $1,361.5 $1,311.4 $71.0 $20.8 $26.6 $0.8 TSX Venture Exchange (TSXV) 20 131.5 123.9 10.8 33 1.2 -3.5 Canadian Securities Exchange (CSE) Af 12.6 72.0 2.0 1.4 1.8 -2.8 Canada 67 $210.6 $203.3 $11.1 $3.8 $4.0 -$2.2 Australian Securities Exchange (ASX) 14 $85.3 $80.1 $5.9 $0.7 $0.9 -$2.1 Australia 14 $85.3 $80.1 $5.9 $07 $0.9 -$2.1 Source: S&P Global Market Intelligence. Companies that are traded on more than one market are included in their primary market as determined by S&P Global Market Intelligence, based on stock price history, trading volume and availability of estimates. Enterprise Value is defined as Market Value plus Debt minus Cash and Cash Equivalents. LTM is Last Twelve Months. EBITDA is defined as Earnings Before Interest, Taxes, Depreciation and Amortization. © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 119

Related Documents (6)

House OversightOtherNov 11, 2025

Compliance Guidance and Sentencing Guidelines Citations in House Oversight Document

The passage consists mainly of citations to compliance manuals, sentencing guidelines, and anti‑corruption resources. It contains no specific allegations, names, transactions, or actionable leads link References to U.S. Sentencing Guidelines and DOJ compliance considerations. Citations of anti‑bribery and corporate compliance literature (e.g., Transparency International, OEC Mentions of debarment

4p
House OversightNov 21, 2016

BofA 2017 Rates, FX & EM Trade Recommendations Referencing Trump and Xi Policies

BofA 2017 Rates, FX & EM Trade Recommendations Referencing Trump and Xi Policies The document is an internal investment strategy memo that mentions political leaders only in the context of macroeconomic forecasts. It contains no concrete allegations, financial flow details, or evidence of misconduct involving high‑level officials, making it a low‑value lead for investigation. Key insights: Predicts two and a half Fed hikes in 2017‑18 despite expected fiscal easing by the Trump administration.; Recommends buying USD/JPY based on anticipated Japanese bond yield policy and a Trump win.; Suggests buying USD call/CNH put, citing a ‘collision course’ between Trump’s need for a weak USD and Xi’s need for a weak CNY.

1p
House OversightUnknown

Empty House Oversight Document Lacks Substantive Content

Empty House Oversight Document Lacks Substantive Content The provided file contains only a title and no substantive text, offering no names, transactions, dates, or allegations to pursue. Consequently, it provides no investigative leads, controversy, novelty, or power linkages. Key insights: Document contains only a header and filename.; No mention of individuals, agencies, or actions.

1p
House OversightFinancial RecordNov 11, 2025

Comprehensive Overview of U.S. AML Laws, Agencies, and Enforcement Actions

The document is a generic reference guide summarizing existing AML statutes, agency roles, and past enforcement actions. It contains no new allegations, specific transactions, or undisclosed relations Lists major U.S. AML statutes (BSA, USA PATRIOT Act, etc.) Identifies federal and non‑bank regulators and law‑enforcement agencies Describes typical enforcement tools (CMPs, DPA, consent orders)

29p
House OversightUnknown

Document alleges extensive financial, academic, and sexual ties between Jeffrey Epstein, Alan Dershowitz, and high‑profile figures including Leslie Wexner, Harvard officials, and political elites

Document alleges extensive financial, academic, and sexual ties between Jeffrey Epstein, Alan Dershowitz, and high‑profile figures including Leslie Wexner, Harvard officials, and political elites The passage provides numerous specific allegations – dates, dollar amounts, meetings, and alleged quid‑pro quo arrangements – that could be pursued for evidence of financial flows, abuse of influence, and coordinated legal obstruction. It implicates powerful actors (Wexner, Harvard leadership, a U.S. state attorney, and potentially members of the British royal family) and suggests systematic surveillance and intimidation of investigators. While many claims are unverified and some are repetitive, the level of detail (e.g., $30 M investment, $1 mansion sale, non‑prosecution agreement clause protecting co‑conspirators) makes it a strong investigative lead. Key insights: 1996 meeting on Epstein’s jet linking Dershowitz to Leslie Wexner’s birthday party.; Epstein’s claim that Wexner sold a Manhattan mansion to him for $1.; 1997 $30 M investment in Boston Provident allegedly sourced from Wexner, with half‑million from Dershowitz.

1p
House OversightMar 11, 2011

Hollywood Oscar Campaign Narrative by Publicist Peggy Siegal

Hollywood Oscar Campaign Narrative by Publicist Peggy Siegal The passage is a promotional, anecdotal recount of Oscar season events and film festival screenings. It mentions industry figures (Harvey Weinstein, Scott Rudin, etc.) but provides no concrete allegations, financial details, or actionable leads linking them to misconduct or illicit activity. The content is largely descriptive and lacks novel, verifiable claims that would merit investigative follow‑up. Key insights: Peggy Siegal describes her role as a publicist covering Oscar campaigns.; Mentions various high‑profile filmmakers and actors (Harvey Weinstein, Scott Rudin, Tom Hooper, Colin Firth).; Describes festival strategies and award‑season lobbying tactics.

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.